Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy
Debiopharm, a Swiss-based biopharmaceutical company announced having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the development of their radioligand program,…